|
Antonio
Colombo, MD 
EMO
Centro Cuore Columbus, San Raffaele Hospital, Italy
| Q > |
1. There have been many studies
and debate for treatment of bifurcation lesion. What is your
treatment strategy for bifurcation lesion? Are there any criterias
for planing 2-stents implantation in bifurcation lesion? |
| |
2. Would you tell us about the AVIO trial?
Do you think using IVUS in complex lesion could improve clinical
outcomes if enough angiographic follow-up would be done? |
| |
3. Based on the several large clinical trials
including SYNTAX and ARTS-II trial, It has been known that the
Syntax score can reflect complexities of anatomy and clinical
outcomes in three-vessel and left main disease. What do you
think about the 'pitfall' of Syntax score? |
|
| |
|
|
Stephen
G. Ellis, MD
The
Cleveland Clinic Foundation, USA
| Q > |
1. Would you tell us about stem
cell therapy for heart disease?
What is the current status of stem cell therapy? |
| |
2. There are several ongoing clinical trials
(TIME, LateTIME, FOCUS trial) evaluating stem cell therapy for
myocardial infarction and chronic ischemic heart disease.
Could you tell us briefly about these clinical trials? Do you
believe that stem cell therapy for ischemic heart disease will
be one of the therapeutic options in the future? |
| |
3. Could you please tell us about the result
and its clinical implications of FINESS trial? |
| |
4. Although the FINESSE trial has not shown
any advantages of facilitated reperfusion over PCI alone, there
is some interesting data that suggest a possible benefit of
lytic and abciximab combination therapy in the high risk group.
What do you think about this subgroup analysis? |
| |
5. Would you tell us about PTMA device for
mitral regurgitation and PTOLEMY study? |
|
| |
|
|
William
F. Fearon, MD
Stanford
University Medicine Center, USA
| Q > |
1. Two years have passed since
you and your colleagues successfully completed the FAME trial
and published the result in the New England Journal of Medicine.
Could you tell us what we learned from the FAME trial and how
it influenced on our daily practice? |
| |
2. To answer the question raised by COURAGE
trial, FAME II trial was planned and it is ongoing now. Could
you briefly summarize the trial and current status? What is
your expectation for the result? |
| |
3. Another large scaled study to evaluate
the role of ischemia guided PCI in the patients with stable
angina, ISCHEMIA trial, is ongoing now. What is the difference
between FAME II and ISCHEMIA trial? |
| |
4. The last question is about IMR, index
of microcirculatory resistance. IMR has been applied to selected
patients subset, especially to the myocardial infarction patients.
Could you tell us your views on how we can apply IMR to the
stable PCI patients? |
|
| |
|
|
Ted
Feldman, MD
Evanston
Hospital, USA
| Q > |
1. 2-year result of EVEREST
II trial was published in NEJM last month.
Would you tell us about the result and its clinical implications
of EVEREST II trial? |
| |
2. Based on the EVEREST trial, you mentioned
that the treatment strategy was based on an individual basis.
Which subgroup do you think is appropriate for percutaneous
repair with MitraClip? |
| |
3. At the first time of this trial, procedure
success rate was around 85%.
Now the success rate is up to 95%.
Could you give us about the tips and tricks for percutaneous
repair with MitraClip? |
| |
4. What kind of changes do you expect in
the future for the percutaneous repair of MR? |
|
| |
|
|
Junbo
Ge, MD
Zhongshan
Hospital, China
| Q > |
1. Could you tell us your perspectives
on the treatment strategy for bifurcation lesion ? |
| |
2. When do you think we should use two stent
technique in the patients with bifurcation lesion? |
| |
3. Could you tell us your views on which
patient group is suitable for percutaneous coronary intervention
in unprotected LM disease? |
|
| |
|
|
Eberhard
Grube, MD
Elisabeth
Hospital Heart Center Rhein-Ruhr, France
| Q > |
1. Experience is extremely important
in successful TAVI procedures.
In order to shorten the learning curve, what do you recommend
to many interventional cardiologists? |
| |
2. Last week, 2-year results of prospective,
multicenter study evaluating safety and efficacy of CoreValve
implantation were published.
Could you explain to us about the results of CoreValve clinical
trial? |
| |
3. Could you introduce 'BioMatris Flex'
stent to our audience?
Could you tell us about the three-year results of LEADERS trial?
|
| |
4. Could you tell us about 'BioFreedom'
polymer-free DES and the result of BIOFREEDOM study? |
|
| |
|
|
David
Richard Holmes, MD
Mayo
Clinic, USA
| Q > |
1. The number of Diabetes patients
is steadily increasing and is predicted to be doubled within
20 years. Could you please tell us the result of BARI-2D trial?
And what do you think the clinical implication of this trial
is? |
| |
2. Could you tell us your views on the treatment
effect of PCI vs CABG in diabetic patients ? |
| |
3. Would you explain the result and clinical
implication of the 'PROTECT AF' trial? |
| |
4. Percutaneous closure with Watchman device
is becoming a much safer procedure as operator experience increases,
according to a comparison of clinical trial(PROTECT AF) and
registry data(Continued Access Registry). Could you tell us
the tips to improve success rate and reduce procedure time ? |
|
| |
|
|
Takeshi
Kimura, MD
Kyoto
University Hospital, Japan
| Q > |
1. Would you tell us about the
result and clinical implication of J-cypher registry for ISR
treatment?
What is the result of subgroup analysis for diabetic patients?
|
| |
2. It has been suggested from ' Registry
of Stent Thrombosis for Review and Reevaluation (RESTART trial)'
that clinical presentation and outcome may vary depending on
the time of stent thrombosis.
Would you tell us about the result and clinical implication? |
| |
3. Would you tell us about the J-CTO registry
and the result of in-hospital outcome after CTO intervention
in Japan?
Could you give us tips and tricks on improving success rate
of CTO intervention? |
|
| |
|
|
Spencer
B. King III, MD
Saint
Joseph's Heart and Vascular Institute, USA
| Q > |
1. Would you tell us about your
treatment strategy for stable ischemic heart disease? |
| |
2. It has been 15 years since the BARI trial
raised concerns about angioplasty in diabetic patients.
Could you tell us about your opinion on the optimal management
strategy for diabetic patients with ischemic heart disease? |
| |
3. From numerous randomized clinical trials,
it is reported that the incidence of 'very late stent thrombosis'
is lesser than 0.5% per year.
What do you think about the main mechanism and predictors of
VLST? |
|
| |
|
|
John
R. Laird, Jr., MD
UC
Davis Medical Center, USA
| Q > |
1. Would you explain the current
treatment strategy for femoropopliteal in-stent restenosis?
What do you think about the role of drug-eluting balloon or
drug-eluting stent for in-stent restenosis lesion? |
| |
2. Could you share us any tips of your own
for successful treatment of Femoropopliteal ISR treatment? |
| |
3. Do you have systematic approach algorithm
for treatment of ISR in peripheral artery? |
| |
4. Would you explain the new treatment guidelines
for carotid artery disease with standard surgical risk? |
|
| |
|
|
Martin
B. Leon, MD
NewYork-Presbyterian
Hospital, CUMC, USA
| Q > |
1. The result of PARTER cohort
B was published in the last year, and the PARTER cohort A was
presented in this year’s ACC meeting.
Could you tell us about the hypothesis, design and the results
of PARTNER trial? |
| |
2. Stroke was a major talking issue in the
PARTNER cohort trials.
Could you tell us about the stroke results in PARTNER trials?
Are there any correctable factors in reducing the risk of stroke? |
| |
3. Rheumatic heart disease is one of the
major causes of aortic stenosis in Asia, especially in Korea.
Do you think that TAVI can be used in the treatment of rheumatic
aortic valve stenosis or in bicuspid valve? |
| |
4. Would that be possible for TAVI to replace
aortic valve surgery in the future? |
|
| |
|
|
Yves
R. Louvard, MD
Institut
Hospitalier Jacques Cartier, France
| Q > |
1. Simple stenting strategy
showed better results than two stent technique in CACTUS and
BBC ONE trials. When do you think we should use two stent technique
in patients with bifurcation lesion? |
| |
2. Could you tell us your perspectives on
final kissing balloon after stentng in bifurcation lesion? Are
there any indications for final kissing balloon? |
| |
3. Because of the large population treated
by PCI, the prevalence of ISR becomes not negligible. Do you
have any treatment strategy for restenosis in stented bifurcation?
|
|
| |
|
|
Akiko
Maehara, MD
Cardiovascular
Research Foundation, USA
| Q > |
1. There were several studies
have validated IVUS-measured MLA as a predictor for abnormal
FFR. Based on those studies, It was shown that IVUS was a very
poor way to assess the physiologic significance of intermediate
lesions. Could you tell us what you think of the role of IVUS
during PCI? |
| |
2. What are your views on the clinical impact
of stent malapposition after primary intervention in AMI patients
based on the IVUS substudy of HORIZON-AMI trial? |
| |
3. Could you tell us the result and its
clinical implication of PROSPECT trial? Based on the PROSPECT
trial, what do you think which lesion should we treat aggressively?
|
| |
4. What do you think of the role of IVUS
and OCT in CTO intervention ? |
|
| |
|
|
Roxana
Mehran, MD
Mount
Sinai Hospital, USA
| Q > |
1. Based on the ACUITY and the
HORIZONS-AMI trials, the risk model that predicts the risk of
major bleeding in ACS patients was published.
Would you tell us about the results of this analysis?
There have been other risk scores for predicting bleeding complication.
What is so unique about your risk score? |
| |
2. Based on TRITON-TIMI 38 trial, Prasugrel
was appoved during PCI in the setting of ACS.
Would you explain to us which group of patients is more favorable
or unfavorable for Prasugrel treatment? |
| |
3. The GRAVITAS trial has shown no additional
benefit of doubling clopidogrel dose for high on-treatment platelet
reactivity.
What is your anti-platelet strategy for patients with clopidogrel
resistance for elective PCI? |
| |
4. Could you tell us about the results and
its clinical implications of SYNTAX and EXCEL trials? |
|
| |
|
|
Gary
S. Mintz, MD
Cardiovascular
Research Foundation, USA
| Q > |
1. Left main stenting is gradually
accumulating more evidences as a treatment option.
Could you tell us about your views on the role of IVUS compared
to FFR during LMCA intervention? |
| |
2. How could we utilize IVUS for optimal
LM stenting? |
| |
3. Could you tell us about the role of IVUS
and OCT in evaluating DES failure? |
| |
4. What do you think about the advantages
of the 2nd generation OCT especially in the complex coronary
lesions? |
| |
5. As a co-director our meeting, would you
give us an advice to TCT-AP? |
|
| |
|
|
Issam
D. Moussa, MD
Weill
Cornell Medical Center, New York Presbyterian Hospital, USA
| Q > |
1. What do you think is the
most important point in below-the-knee intervention? |
| |
2. Many clinical studies have been going
on since the CLOSURE study.
Would you tell us briefly about your future study plans? |
| |
3. Do you believe that the protection device
is harmful in carotid intervention?
What type of protection device do you believe is the most ideal?
|
|
| |
|
|
Seung-Jung
Park, MD
Asan
Medical Center, Korea(Republic of)
| Q > |
1. What does the result of PRECOMBAT
trial indicate, and could you tell us about what kind of influences
it might have on actual clinical practices? |
| |
2. What is the difference between PRECOMBAT
and SYNTAX trial? |
| |
3. What is the main purpose of FFR-guided
procedure? |
| |
4. For accurate and proper FFR-guided procedure,
what are the things that operators need to know? |
|
| |
|
|
Matthew
Price, MD
Scripps
Clinic, USA
| Q > |
1. Would you tell us about the
design and main results of the GRAVITAS trial? |
| |
2. GRAVITAS trial did not show better outcome
in the high-dose clopidogrel group.
What do you think about the role of anti-platelet function test? |
| |
3. It seems that the patients in GRAVITAS
trial were not high-risk enough to show any meaningful effects
of higher clopidogrel dose.
What do you expect about the effects of higher dose of clopidogrel
in patients with ACS?
Do you think there should be a cut off PRU level where cardiovascular
events start to increase? |
| |
4. In the ACC meeting this meeting, the
GRAVITAS genetic sub-group study(GIFT) was presented. Could
you tell us about the main message of this genetic study? |
|
| |
|
|
Barry
D. Rutherford, MD
Saint
Luke's Mid America Heart Institute, USA
| Q > |
1. Could you tell us about your
views on the effects of thrombectomy in patients with STEMI?
|
| |
2. What do you think about routine thrombectomy
in STEMI patients even without visible thrombus?
Do you think there are indications for thrombectomy in patients
with ACS? |
| |
3. Are there any ongoing clinical trials
comparing the efficacy and safety of thrombectomy in patient
with ACS? |
|
| |
|
|
Patrick
W. Serruys, MD
Erasmus
Medical Center-Thoraxcenter, Netherlands
| Q > |
1. Could you tell us about the
common complications of TAVI?
Could you tell us about the management strategy for each complication?
Could you give us about your tips in reducing these complications?
|
| |
2. Results of the second phase of the ABSORB
trial were presented in the ACC meeting this year.
Could you tell us about 'Bioabsorbable everolimus-eluting stent'?
Could you tell us about the study design and the results of
ABSORB trial? |
| |
3. Could you tell us about the results and
its clinical implications of LEADERS trial using BioMatrix Flex
stent? |
| |
4. Could you tell us about the 3-year follow-up
results of SYNTAX trial?
Did you find any different outcomes in LM disease and three-vessel
disease subgroups? |
|
| |
|
|
Horst
Sievert, MD
CardioVascular
Center Frankfurt, Germany
| Q > |
1. Would you tell us about the
results and clinical implications of the 'PROTECT AF' trial
with Watchman device? |
| |
2. Would you tell us about the Amplatzer
cardiac plug for percutaneous left atrial appendage closure?
What are the anatomical indications and contraindication for
Amplatzer cardiac plug? |
| |
3. Could you please tell us about the tips
and tricks for improving success rate and reducing procedure
time for percutaneous left atrial appendage closure? |
|
| |
|
|
Gregg
W. Stone, MD
Columbia
University Medical Center, Cardiovascular Research Foundation, USA
| Q > |
1. EXCEL trial is ongoing now.
Would you tell us about the clinical design and the purpose
of EXCEL trial? Could you tell us the current status of this
trial? |
| |
2. Could you tell us 2-year result of SPIRIT
IV trial? |
| |
3. In the SPIRIT IV trial, superiority of
Everolimus over Paclitaxel stent does not extend to diabetic
patients. Do you think there are any reasons to explain this
result ? |
| |
4. Would you tell us about the Promus Element™
Platinum Chromium Stent ? What is the result of 12-month result
of 'PLATINUM Workhorse trial' ? |
|
| |
|
|
Ron
Waksman, MD
Washington
Hospital Center, USA
| Q > |
1. Platelet reactivity and response
to antiplatelet therapy may vary depending on various clinical
factors.
What do you think about the role of platelet function and genomic
testing in oral antiplatelet treatment strategy? |
| |
2. There has been great effort in identifying
vulnerable plaque with higher risk of future cardiovascular
events.
Could you tell us about your views on the 'vulnerable plaque'? |
| |
3. Would you tell us about the concept of
'DREAMS'(Drug-Eluting Absorbable Metal Stent) as a new type
of DES and the current status of clinical trials?
Could you tell us about your views on the future direction of
bioabsorbable stent? |
| |
4. As a chairman of CRT, which is one of
the most important interventional cardiology meetings in the
U.S, please give us your advices to TCT-AP meeting.
What are the most important factors we should focus on in our
TCT-AP meeting? |
|
|
|
